Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Lidak Pharm. [LDAKA] -- Ignore unavailable to you. Want to Upgrade?

To: Red Dragon who wrote (823)	1/9/1998 10:24:00 AM
From: MCorbley	Respond to of 1115

BIG mistake by me regarding Lidakol and Zovirax: I can't believe that I posted it twice without catching my typo: Likdaol was comparable to Zovirax cream, which is not available in the U.S. Zovirax cream is significantly BETTER than Zovirax ointment. Zovirax ointment is marketed in the U.S. for limited use in other herpes infections. Also: (In Europe) "achieving comparable activity to an existing approved drug is a positive outcome since it satisfies one important criterion for registration in many European countries." (press release 1995)

To: Red Dragon who wrote (823)	1/9/1998 10:28:00 AM
From: MCorbley	Respond to of 1115

Therefore my posts 433 and 818 should read: Lidakol vs. Zovirax: In 1995, Lidak reported the results of a study comparing Lidakol to Zovirax (aciclovir) 5% cream in 326 patients. Lidakol demonstrated "statistically comparable therapeutic efficacy to Zovirax 5% cream." (quote from annual report). Zovirax 5% cream is the standard approved treatment for cold sores in Europe, but is not available in the U.S. This study was used to show that Lidakol was as effective as the best treatment available, and by inference that Lidakol is effective--period. Lidak also pointed out that Zovirax 5% cream is not the same as, and is superior to, Zovirax 5% ointment, which is available in the U.S. for limited use in other herpes infections but not for recurrent oral infections. That was in 1995. European sales of Zovirax were $125 million US dollars in 1994.